Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money

Some stocks are similar to the tortoise in Aesop's famous fable, "The Tortoise and the Hare." Others are like the hare. But the best stocks mirror hares that don't slow down and take breaks, as the one described by Aesop did. They're the kind that win the race every single time.

I think three stocks have the speed of Aesop's hare and the persistence of his tortoise. If you've got $5,000 to invest, these top growth stocks could double your money over time.

Image source: Getty Images.

1. Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (NASDAQ: ALNY) pioneered RNA interference (RNAi), an approach where messenger RNA (mRNA) is targeted before it can deliver instructions on how to build proteins. The company now has six approved RNAi therapies on the market, two of which are outlicensed to other drugmakers.

In the third quarter of 2025, Alnylam's revenue skyrocketed 149% year over year to $1.25 billion. The biotech innovator also posted a quarterly profit for only the third time since its initial public offering in 2004. I think that profitability won't be fleeting this time.

The key behind Alnylam's growth (and a top reason why it could double investors' money) is Amvuttra. The RNAi therapy won U.S. Food and Drug Administration approval for treating cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) earlier this year. Alnylam also has seven promising late-stage clinical programs that could be big growth drivers over the next several years.

To be sure, Alnylam faces risks. Its pipeline candidates could flop in clinical trials. Other drugmakers could launch more powerful therapies. Significant growth expectations are also already baked into Alnylam's share price, with its forward price-to-earnings ratio of 46.5. However, I predict that this biotech stock will continue its winning ways for a long time to come.

2. IonQ

Quantum computing has become one of the hottest technologies around. IonQ (NYSE: IONQ) began developing quantum computers in 2015. Today, the company has over 1,100 patents on its technology and has built its fifth generation of quantum computers.

IonQ's revenue soared 222% year over year in Q3 to $39.9 million. Its revenue has increased by a compound annual growth rate of 168% since 2021. The company also further bolstered its capabilities with the acquisitions of Oxford Ionics and Vector Atomic. In addition, IonQ formed a unit to focus on meeting the increasing demand for quantum computing with the U.S. and other governments.

How could IonQ double your money? The company's quantum technology must scale up to handle more complex, real-world problems. IonQ believes it's on track to achieve this goal, with a roadmap to support 80,000 logical qubits (the basic unit of information in quantum computing) by 2030.

Of course, there's no guarantee that IonQ will be able to deliver on its roadmap. It's also possible that competing quantum computing approaches could prove to be superior to the company's trapped-ion architecture. But this stock could very well be a huge moneymaker for aggressive investors who aren't risk-averse.

3. Toast

Toast (NYSE: TOST) operates a cloud-based platform that helps restaurants run their businesses. Around 156,000 restaurants use its technology to handle payments, support digital ordering and delivery, manage customer loyalty programs, and more.

The company's annualized recurring revenue run rate jumped 30% year over year in Q3 to $2 billion. Its gross payment volume jumped 24%. Earnings almost doubled year over year to $105 million. And the total number of locations using Toast's platform increased 23%.

Toast's share price has more than doubled since the current bull market began in late 2023. The stock's path to doubling again is for the company to keep doing what it's been doing: gaining market share and introducing new products and services.

Perhaps the biggest obstacle that could get in the way of Toast doubling investors' money is a severe economic downturn that resulted in widespread closures of restaurants. However, the long-term prospects of the restaurant industry -- and Toast -- appear to be strong.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alnylam Pharmaceuticals, IonQ, and Toast. The Motley Fool has a disclosure policy.